AstraZeneca PLC (LON:AZN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is £145.83.

Several research firms have commented on AZN. Berenberg Bank boosted their price objective on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Deutsche Bank Aktiengesellschaft increased their target price on shares of AstraZeneca from £105 to £110 and gave the company a “sell” rating in a report on Thursday, January 15th. Citigroup assumed coverage on shares of AstraZeneca in a research report on Tuesday, January 27th. They issued a “buy” rating and a £170 target price on the stock. Shore Capital Group reissued a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th.

AstraZeneca Stock Performance

LON:AZN opened at £143.96 on Wednesday. The company has a market capitalization of £223.25 billion, a price-to-earnings ratio of 22.01, a PEG ratio of 0.86 and a beta of 0.23. The business has a 50 day moving average of £144.16 and a 200 day moving average of £134. The company has a debt-to-equity ratio of 60.87, a current ratio of 0.94 and a quick ratio of 0.59. AstraZeneca has a 1-year low of GBX 9,573.51 and a 1-year high of £157.32.

Insiders Place Their Bets

In related news, insider Nazneen Rahman sold 297 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. 0.14% of the stock is owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.